1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Donaldson, L.W. Pawson, T. Kay, L.E. Forman-Kay, J.D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C9 H12 N O6 P 261.168 n O-PHOSPHOTYROSINE PHOSPHONOTYROSINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 99 14053 14058 10.1073/pnas.212518799 12384576 Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide 2002 10.2210/pdb1ju5/pdb pdb_00001ju5 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 12142.571 Crk Crk SH2 domain 1 man polymer 1468.480 Crk Crk phosphopeptide 1 man polymer 6764.461 Abl 2.7.1.112 Abl SH3 domain L122K 1 man polymer PROTO-ONCOGENE C-CRK, ADAPTER MOLECULE CRK, P38 PROTO-ONCOGENE C-CRK, ADAPTER MOLECULE CRK, P38 proto-oncogene tyrosine-protein kinase no no SWYWGRLSRQEAVALLQGQRHGVFLVRDSSTSPGDYVLSVSENSRVSHYIINSSGPRPPVPPSPAQPPPGVSPSRLRIGD QEFDSLPALLEFYKIHYLDTTTLIEPVSR SWYWGRLSRQEAVALLQGQRHGVFLVRDSSTSPGDYVLSVSENSRVSHYIINSSGPRPPVPPSPAQPPPGVSPSRLRIGD QEFDSLPALLEFYKIHYLDTTTLIEPVSR A polypeptide(L) no yes EPGP(PTR)AQPSVNTK EPGPYAQPSVNTK B polypeptide(L) no no DPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSK DPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSK C polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia Escherichia coli sample 9606 Homo sapiens 511693 Escherichia coli BL21 BL21 plasmid pGEX-2T house mouse Mus Escherichia Escherichia coli sample 10090 Mus musculus 511693 Escherichia coli BL21 BL21 PLASMID pAED4-MMHB human Homo Escherichia Escherichia coli sample 9606 Homo sapiens 511693 Escherichia coli BL21 BL21 PLASMID pET15 database_2 pdbx_struct_assembly pdbx_struct_oper_list struct_conn struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2002-11-06 1 1 2008-04-27 1 2 2011-07-13 1 3 2021-11-10 _database_2.pdbx_DOI _database_2.pdbx_database_accession _struct_conn.pdbx_leaving_atom_flag _struct_ref_seq_dif.details 1AWO contains NMR structure of Abl SH3 domain in an SH(32) fragment 1BBZ contains Crystal structure of Abl SH3 domain with high-affinity ligand 2ABL contains Sh3-Sh2 Domain Fragment Of Human Bcr-Abl Tyrosine Kinase 1AYA contains Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. 2PLD contains Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-1 complexed with a high affinity binding peptide. 1SPS contains Crystal structure of the Src SH2 in complex with YEEI RCSB Y PDBJ 2001-08-23 REL REL Intermolecular distance restraints were obtained from reverse half-filtered 2D- and 3D-NOESY spectra (300 ms mixing time) on sample in 99% D2O. Methyl prochiral assignments were made on a 10% 13C-labeled sample according to Neri et al (Biochemistry 28:7510; 1989). HACAN and CBCA(CO)N(CA)HA experiments were used to assign the proline residues in the Crk SH2 domain according to Kanelis et al (JBNMR 16:253; 2000) structures with the lowest energy 40 1 3D_13C-separated_NOESY 3D_15N-separated_NOESY 3D_13C_F1-FILTERED_F3-EDITED_NOESY J-HNHA IPAP-15N_HSQC 50mM sodium phosphate 6.8 ambient 303 K This structure represents the lowest energy solution based on 2406 SH2 intramolecular restraints, 1628 SH3 intramolecular restraints, 37 SH2-SH3 intermolecular restraints, 64 SH2-phosphopeptide intermolecular restraints, 50 hydrogen bonds, 54 direct 3J-HNHA couplings and 166 dihedral angle restraints from TALOS Residues 217-220 and 225-229 of the Crk phosphopeptide (Chain B) are disordered. As intermolecular contacts between the SH2 domain (Chain A) and the SH3 domain (Chain C) limited to amino acids 67-75 in DE-loop of the SH2 domain, there is no unique orientation between the SH2 domain and SH3 domain. ARIA 1.0, CNS 1.0 1 lowest energy 0.6-1.5mM Crk SH2 domain U-15N, 13C; 50mM sodium phosphate pH6.8, 0.02% sodium azide 90% H2O/10% D2O Delaglio processing NMRPipe 1.8 Garrett data analysis PIPP 4.3.2 Brunger structure solution CNS 1.0 Brunger structure solution ARIA 1.0 Brunger refinement ARIA 1.0 500 Varian UNITYPLUS 600 Varian UNITYPLUS 800 Varian UNITYPLUS SER 12 n 1 SER 12 A TRP 13 n 2 TRP 13 A TYR 14 n 3 TYR 14 A TRP 15 n 4 TRP 15 A GLY 16 n 5 GLY 16 A ARG 17 n 6 ARG 17 A LEU 18 n 7 LEU 18 A SER 19 n 8 SER 19 A ARG 20 n 9 ARG 20 A GLN 21 n 10 GLN 21 A GLU 22 n 11 GLU 22 A ALA 23 n 12 ALA 23 A VAL 24 n 13 VAL 24 A ALA 25 n 14 ALA 25 A LEU 26 n 15 LEU 26 A LEU 27 n 16 LEU 27 A GLN 28 n 17 GLN 28 A GLY 29 n 18 GLY 29 A GLN 30 n 19 GLN 30 A ARG 31 n 20 ARG 31 A HIS 32 n 21 HIS 32 A GLY 33 n 22 GLY 33 A VAL 34 n 23 VAL 34 A PHE 35 n 24 PHE 35 A LEU 36 n 25 LEU 36 A VAL 37 n 26 VAL 37 A ARG 38 n 27 ARG 38 A ASP 39 n 28 ASP 39 A SER 40 n 29 SER 40 A SER 41 n 30 SER 41 A THR 42 n 31 THR 42 A SER 43 n 32 SER 43 A PRO 44 n 33 PRO 44 A GLY 45 n 34 GLY 45 A ASP 46 n 35 ASP 46 A TYR 47 n 36 TYR 47 A VAL 48 n 37 VAL 48 A LEU 49 n 38 LEU 49 A SER 50 n 39 SER 50 A VAL 51 n 40 VAL 51 A SER 52 n 41 SER 52 A GLU 53 n 42 GLU 53 A ASN 54 n 43 ASN 54 A SER 55 n 44 SER 55 A ARG 56 n 45 ARG 56 A VAL 57 n 46 VAL 57 A SER 58 n 47 SER 58 A HIS 59 n 48 HIS 59 A TYR 60 n 49 TYR 60 A ILE 61 n 50 ILE 61 A ILE 62 n 51 ILE 62 A ASN 63 n 52 ASN 63 A SER 64 n 53 SER 64 A SER 65 n 54 SER 65 A GLY 66 n 55 GLY 66 A PRO 67 n 56 PRO 67 A ARG 68 n 57 ARG 68 A PRO 69 n 58 PRO 69 A PRO 70 n 59 PRO 70 A VAL 71 n 60 VAL 71 A PRO 72 n 61 PRO 72 A PRO 73 n 62 PRO 73 A SER 74 n 63 SER 74 A PRO 75 n 64 PRO 75 A ALA 76 n 65 ALA 76 A GLN 77 n 66 GLN 77 A PRO 78 n 67 PRO 78 A PRO 79 n 68 PRO 79 A PRO 80 n 69 PRO 80 A GLY 81 n 70 GLY 81 A VAL 82 n 71 VAL 82 A SER 83 n 72 SER 83 A PRO 84 n 73 PRO 84 A SER 85 n 74 SER 85 A ARG 86 n 75 ARG 86 A LEU 87 n 76 LEU 87 A ARG 88 n 77 ARG 88 A ILE 89 n 78 ILE 89 A GLY 90 n 79 GLY 90 A ASP 91 n 80 ASP 91 A GLN 92 n 81 GLN 92 A GLU 93 n 82 GLU 93 A PHE 94 n 83 PHE 94 A ASP 95 n 84 ASP 95 A SER 96 n 85 SER 96 A LEU 97 n 86 LEU 97 A PRO 98 n 87 PRO 98 A ALA 99 n 88 ALA 99 A LEU 100 n 89 LEU 100 A LEU 101 n 90 LEU 101 A GLU 102 n 91 GLU 102 A PHE 103 n 92 PHE 103 A TYR 104 n 93 TYR 104 A LYS 105 n 94 LYS 105 A ILE 106 n 95 ILE 106 A HIS 107 n 96 HIS 107 A TYR 108 n 97 TYR 108 A LEU 109 n 98 LEU 109 A ASP 110 n 99 ASP 110 A THR 111 n 100 THR 111 A THR 112 n 101 THR 112 A THR 113 n 102 THR 113 A LEU 114 n 103 LEU 114 A ILE 115 n 104 ILE 115 A GLU 116 n 105 GLU 116 A PRO 117 n 106 PRO 117 A VAL 118 n 107 VAL 118 A SER 119 n 108 SER 119 A ARG 120 n 109 ARG 120 A GLU 217 n 1 GLU 217 B PRO 218 n 2 PRO 218 B GLY 219 n 3 GLY 219 B PRO 220 n 4 PRO 220 B TYR 221 n 5 PTR 221 B ALA 222 n 6 ALA 222 B GLN 223 n 7 GLN 223 B PRO 224 n 8 PRO 224 B SER 225 n 9 SER 225 B VAL 226 n 10 VAL 226 B ASN 227 n 11 ASN 227 B THR 228 n 12 THR 228 B LYS 229 n 13 LYS 229 B ASP 62 n 1 ASP 62 C PRO 63 n 2 PRO 63 C ASN 64 n 3 ASN 64 C LEU 65 n 4 LEU 65 C PHE 66 n 5 PHE 66 C VAL 67 n 6 VAL 67 C ALA 68 n 7 ALA 68 C LEU 69 n 8 LEU 69 C TYR 70 n 9 TYR 70 C ASP 71 n 10 ASP 71 C PHE 72 n 11 PHE 72 C VAL 73 n 12 VAL 73 C ALA 74 n 13 ALA 74 C SER 75 n 14 SER 75 C GLY 76 n 15 GLY 76 C ASP 77 n 16 ASP 77 C ASN 78 n 17 ASN 78 C THR 79 n 18 THR 79 C LEU 80 n 19 LEU 80 C SER 81 n 20 SER 81 C ILE 82 n 21 ILE 82 C THR 83 n 22 THR 83 C LYS 84 n 23 LYS 84 C GLY 85 n 24 GLY 85 C GLU 86 n 25 GLU 86 C LYS 87 n 26 LYS 87 C LEU 88 n 27 LEU 88 C ARG 89 n 28 ARG 89 C VAL 90 n 29 VAL 90 C LEU 91 n 30 LEU 91 C GLY 92 n 31 GLY 92 C TYR 93 n 32 TYR 93 C ASN 94 n 33 ASN 94 C HIS 95 n 34 HIS 95 C ASN 96 n 35 ASN 96 C GLY 97 n 36 GLY 97 C GLU 98 n 37 GLU 98 C TRP 99 n 38 TRP 99 C CYS 100 n 39 CYS 100 C GLU 101 n 40 GLU 101 C ALA 102 n 41 ALA 102 C GLN 103 n 42 GLN 103 C THR 104 n 43 THR 104 C LYS 105 n 44 LYS 105 C ASN 106 n 45 ASN 106 C GLY 107 n 46 GLY 107 C GLN 108 n 47 GLN 108 C GLY 109 n 48 GLY 109 C TRP 110 n 49 TRP 110 C VAL 111 n 50 VAL 111 C PRO 112 n 51 PRO 112 C SER 113 n 52 SER 113 C ASN 114 n 53 ASN 114 C TYR 115 n 54 TYR 115 C ILE 116 n 55 ILE 116 C THR 117 n 56 THR 117 C PRO 118 n 57 PRO 118 C VAL 119 n 58 VAL 119 C ASN 120 n 59 ASN 120 C SER 121 n 60 SER 121 C n 61 122 C author_defined_assembly 3 trimeric B PTR 221 O-PHOSPHOTYROSINE B PTR 5 TYR 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 A O ILE 62 A O ILE 51 A N TYR 47 A N TYR 36 A O SER 50 A O SER 39 A N LEU 36 A N LEU 25 A O VAL 37 A O VAL 26 A N TRP 15 A N TRP 4 A O ILE 62 A O ILE 51 A N TYR 47 A N TYR 36 A O SER 50 A O SER 39 A N LEU 36 A N LEU 25 A N PHE 35 A N PHE 24 A O GLU 116 A O GLU 105 A N ILE 89 A N ILE 78 A O GLN 92 A O GLN 81 C O VAL 111 C O VAL 50 C N CYS 100 C N CYS 39 C O GLN 103 C O GLN 42 C N ARG 89 C N ARG 28 C O LEU 88 C O LEU 27 C N PHE 66 C N PHE 5 C N VAL 67 C N VAL 6 C O THR 117 C O THR 56 1 C LYS 122 C LYS 61 1 Y 1 A ARG 31 -49.28 164.49 1 A GLU 53 -75.02 -160.31 1 A SER 55 80.47 14.86 1 A PRO 75 -49.77 164.09 1 A SER 83 -151.10 89.59 1 A TYR 108 -108.61 45.86 1 A THR 112 47.45 -176.15 1 B GLN 223 69.82 95.24 1 B SER 225 -133.71 -46.51 1 B VAL 226 53.63 71.30 1 B ASN 227 -138.22 -74.76 1 B THR 228 53.34 -170.68 1 C ASN 64 -176.91 40.61 1 C ASP 77 -57.31 -161.80 1 C PRO 112 -49.94 163.62 Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectroscopy 1 N N 2 N N 3 N N A SER 19 A SER 8 HELX_P A GLN 28 A GLN 17 1 1 10 A SER 96 A SER 85 HELX_P A HIS 107 A HIS 96 1 2 12 covale 1.329 both B PRO 220 B C PRO 4 1_555 B PTR 221 B N PTR 5 1_555 covale 1.330 both B PTR 221 B C PTR 5 1_555 B ALA 222 B N ALA 6 1_555 PROTEIN BINDING/TRANSFERASE Crk, SH2, Abl, SH3, adaptor protein, phosphopeptide, PROTEIN BINDING-TRANSFERASE COMPLEX CRK_HUMAN UNP 1 P46108 CRK_MOUSE UNP 2 Q64010 ABL1_HUMAN UNP 3 P00519 12 120 1JU5 12 120 P46108 A 1 1 109 217 228 1JU5 217 228 Q64010 B 2 1 12 62 122 1JU5 62 122 P00519 C 3 1 61 3 LEU engineered mutation LYS 122 1JU5 C P00519 UNP 122 61 4 4 2 5 anti-parallel anti-parallel parallel anti-parallel anti-parallel parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A VAL 57 A VAL 46 A ASN 63 A ASN 52 A ASP 46 A ASP 35 A SER 52 A SER 41 A VAL 34 A VAL 23 A ASP 39 A ASP 28 A TYR 14 A TYR 3 A TRP 15 A TRP 4 A VAL 57 A VAL 46 A ASN 63 A ASN 52 A ASP 46 A ASP 35 A SER 52 A SER 41 A VAL 34 A VAL 23 A ASP 39 A ASP 28 A GLU 116 A GLU 105 A PRO 117 A PRO 106 A LEU 87 A LEU 76 A ILE 89 A ILE 78 A GLN 92 A GLN 81 A PHE 94 A PHE 83 C GLY 107 C GLY 46 C PRO 112 C PRO 51 C TRP 99 C TRP 38 C THR 104 C THR 43 C LYS 87 C LYS 26 C TYR 93 C TYR 32 C PHE 66 C PHE 5 C ALA 68 C ALA 7 C ILE 116 C ILE 55 C PRO 118 C PRO 57